HCC - HEPATOCELLULAR CARCINOMA

This study tests a combination of targeted radiation (SBRT) and an experimental drug called QL1706 in 36 adults with advanced liver cancer that has worsened after one prior treatment. The radiation is given to liver tumors over five sessions, followed by QL1706 infusions every th…

This study tests a combination of four drugs (epalrestat, HAIC, donafenib, and tislelizumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery and who also have diabetes. The goal is to see if this approach can control the cancer for at …

This study tests whether giving a combination of chemotherapy directly into the liver (HAIC) plus two drugs (camrelizumab and apatinib) before and after surgery can prevent liver cancer from returning in high-risk patients. About 208 people with resectable liver cancer and high-r…

This study is for people with liver cancer that cannot be removed by surgery. Researchers want to find the exact amount of radiation needed to completely destroy the tumor using a special procedure called Y90 radioembolization. About 30 adults will take part to help improve treat…

This phase 2 trial tests a combination of two targeted drugs (donafenib and sintilimab) plus chemotherapy delivered directly to the liver as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study will enroll 90 participants and measur…

This study tests a combination of three drugs—firsekibart, tislelizumab, and lenvatinib—in people with advanced liver cancer that has a specific genetic change called a TP53 mutation. Participants must have already tried immunotherapy without success. The goal is to see if this d…

This phase II trial tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can reduce the risk of liver cancer returning in patients with early-stage disease and narrow surgical margins. Sixty participants will be randomly assigned to receive the drug combina…

This study tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 30 adults with early-stage liver cancer (stage IB or IIA) will receive…

This phase 3 study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 198 adults with early-stage liver cancer will be enrolled. The main goal is to see if this app…

This phase 2 trial tests whether adding branched-chain amino acids (BCAAs) to the drugs lenvatinib and pembrolizumab helps adults with unresectable liver cancer live longer without their cancer worsening. About 234 participants will be randomly assigned to receive the standard tw…

This study looks at 100 liver cancer patients whose tumors shrank or disappeared after initial therapy. It compares two follow-up options: surgery to remove any remaining cancer, or continuing medication (maintenance therapy). The goal is to see which approach better prevents the…

This study tests a three-part treatment for people with liver cancer that has spread into the main vein of the liver (portal vein tumor thrombus). Participants will receive radiation therapy, followed by two drugs (tislelizumab and anlotinib) to boost the immune system and block …

This study tests whether taking a probiotic (Lactobacillus reuteri) before surgery can improve the effects of immunotherapy in people with liver cancer. About 40 adults with resectable liver cancer will either receive the probiotic plus immunotherapy or immunotherapy alone before…

This study tests whether adding a nerve-zapping procedure called endovascular denervation (EDN) to standard liver cancer treatments (TACE/HAIC and immune-targeted drugs) can improve outcomes for people with advanced liver cancer that has spread to the portal vein and stopped resp…

This study tests whether offering free rideshares, hotel stays, and meal delivery helps low-income liver cancer patients start treatment sooner. About 75 uninsured or underinsured adults with liver cancer will be randomly assigned to receive these social supports plus usual patie…

This study will use artificial intelligence to analyze CT scans and medical data from 400 liver cancer patients to predict who will respond to a common drug combination (atezolizumab and bevacizumab). The goal is to create a non-invasive tool that helps doctors choose the best tr…